阿托伐他汀对强直性脊柱炎患者外周血单个核细胞体外干预后Toll样受体2、Toll样受体4的表达变化研究  

Expression of Toll-like receptor 2 and Toll-like receptor 4 after intervention by Atorvastatin work on peripheral blood mononuclear cells of ankylosing spondylitis patients

作　　者：毋静[1] 梁婉怡[1] 邓家鑫[1] 曲源[1] 于清宏[1] 

机构地区：[1]南方医科大学珠江医院风湿免疫科,广州510280

出　　处：《中国医药导报》2012年第1期25-27,共3页China Medical Herald

摘　　要：目的:观察天然免疫分子Toll样受体2(TLR-2)、Toll样受体4(TLR-4)在强直性脊柱炎(ankylosing spondyli-tis,AS)患者外周血单个核细胞(peripheral blood mononuclear cells,PBMC)的mRNA水平表达,研究其与AS发病的相关性,并探讨阿托伐他汀是否对AS患者TLR-2、TLR-4的表达有影响。方法:研究对象包括AS活动期患者30例和健康志愿者30例,分别抽取外周静脉血分离单个核细胞,提取细胞mRNA。采用半定量的RT-PCR方法,检测AS患者和健康志愿者外周血单个核细胞中TLR-2、TLR-4的mRNA,通过灰度分析与β-actin相比得到目的基因相对表达水平。分离12例AS活动期患者静脉血外周血单个核细胞体外培养,并给予阿托伐他汀(终浓度为0.01 mmol/L)处理,以自身非处理细胞为对照,24 h后收获细胞,提取mRNA,采用RT-PCR方法,观察阿托伐他汀对细胞TLR-2、TLR-4的mRNA表达的影响。所有数据采用配对t检验。结果:AS患者TLR-2 mRNA的相对表达水平为(1.59±1.43),较健康志愿者(0.06±0.039)高(P<0.05);AS患者TLR-4 mRNA的相对表达水平为(0.60±0.73),较健康志愿者(0.06±0.039)高(P<0.05);阿托伐他汀干预组TLR-2和TLR-4的mRNA表达均低于不干预对照组(P<0.05)。结论:AS患者PBMC的TLR-2、TLR-4的表达均较健康志愿者高,提示TLR-2和TLR-4可能参与了AS的发病。阿托伐他汀可下调AS患者PBMC的TLR-2和TLR-4的表达,可能是AS新的有价值的治疗靶点之一。Objective： To study the expression and regulation on TLR-2 and TLR-4 after intervention by Atorvastatin working on the peripheral blood mononuclear cells（PBMC） of ankylosing spondylitis patients.Methods： The study was designed to enroll 30 cases of AS and 30 cases of healthy controls.The expression levels of TLR-2 and TLR-4 in PBMC were determined by RT-PCR technical through comparing with β-actin,used t-test to compare the means.In vitro effect of Atorvastatin（0.01 mmol/L） working on PBMC of ankylosing spondylitis patients,12 cases were entrolled in.PBMC from one patient were divided into two groups.One was treated with Atorvastatin（0.01 mmol/L）,another was control.The different expression levels of TLR-2 and TLR-4 with or without treated by Atorvastatin were also determined by RT-PCR method.Paired-t test was used to calculate the results.Results： The TLR-2 mRNA expression level of AS patients was higher（1.59±1.43） than control（0.06±0.039）（P0.05）.The TLR-4 mRNA expression level of AS patients was higher（0.60±0.73） than control（0.06±0.039）（P0.05）.Atorvastatin down regulated TLR-2 mRNA and TLR-4 mRNA in PBMC of AS patients in vitro test.After analysed by paired-t test,the result showed that it was more remarkable that Atorvastatin reduced the expression level of TLR-2 mRNA and TLR-4 mRNA in AS patients than control（P0.05） respectively.Conclusion： The mRNA expression levels of TLR-2 and TLR-4 in AS patients are higher than that in controls,which may play an important role in immune reaction of AS.Atorvastatin has an effect to reduce the expression of TLR-2 mRNA and TLR-4 mRNA in PBMC of AS patients.It is possible that Atorvastatin is a potential and useful medicine of AS in future.

关 键 词：强直性脊柱炎 TOLL样受体 阿托伐他汀 

分 类 号：R593.23[医药卫生—内科学]